Item 2.02Results of Operations and Financial Condition.

On August 9, 2022, Olema Pharmaceuticals, Inc. (the "Company") reported its financial results for the quarter ended June 30, 2022. A copy of the press release is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On August 9, 2022, the Company issued a press release titled "Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer." A copy of the press release is furnished pursuant to item 7.01 as Exhibit 99.2 and is incorporated herein by reference.

The information in Item 2.02, including the press release attached as Exhibit 99.1 hereto, and in item 7.01, including the press release attached as Exhibit 99.2 hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Olema Pharmaceuticals, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.



Item 9.01        Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.      Description
                   Press release, dated August 9, 2022, of Olema
    99.1         Pharmaceuticals, Inc.
                   Press release, dated August 9, 2022, of Olema Pharmaceuticals,
    99.2         Inc.
                 Cover Page Interactive Data File (embedded within the Inline XBRL
104              document).

© Edgar Online, source Glimpses